News and Announcements
Sementis Ltd – CEO Interview
- Published November 13, 2014 11:53AM UTC
- Publisher Wholesale Investor
- Categories Executive Interviews
Sementis is a biotech company developing vaccines for peanut allergy and chikungunya (like dengue fever, a mosquito-borne disease spreading throughout the world). There is an early stage pipeline for vaccines for Ebola, Q Fever, Melanoma (skin Cancer) and prostate Cancer.
The vaccines use Sementis’ “SCV” backbone technology. This is a vaccinia virus (which is also a smallpox vaccine) genetically altered to prevent replication in human cells thus ensuring safety and, through further manipulation, able to increase its immune stimulating properties. The genes for antigens from diseases are added to the SCV, which, with vaccination, elicits an immune response to the disease state in the human body.
Sementis’ Non-executive Chairman, Maurice O’Shannassy spent 25 years in the financial services industry in Australia, the United Kingdom and Asia. His most recent role was that of CEO of BlackRock Investment Management in Australia. Prior to that he was the CEO and CIO of the Asian operations of BlackRock’s antecedents, Merrill Lynch Investment Management and Mercury Asset Management.
Please listen to Sementis’ Non-executive Chairman, Mr. Maurice O’Shannassy.
Executive Interviews
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Asset over thematic: Centuria’s Andrew Essey warns against ‘blanket strategies’ as global capital eyes Australia
Relying solely on broad macroeconomic trends is the single biggest mistake property investors make today. Centuria Capital CIO Andrew Essey explains why asset-level “lettability” always trumps the overarching sector thematic, and reveals where global institutional capital is quietly pivoting to capture high-octane returns.
Material gains: Swinburne spin-out EntroMat takes aim at $160b global market
Traditional metallurgy has hit a performance wall. Discover how Swinburne University spin-out EntroMat is leveraging physics-based AI and circular critical minerals to engineer high-entropy alloys capable of surviving the world’s most extreme industrial environments.
Backed By Leading Investment Groups and Family Offices
